lines derived from malignant mesotheliomas (MMs),
lines derived from malignant mesotheliomas (MMs), germ cell neoplasms, and colon carcinomas. Thus, the investigators proposed that alterations of BCL10 may contribute to the pathogenesis of several types of neoplasia.
The observation of most interest to us was that BCL10, which maps to chromosome 1p22, exhibited mutations in all three MM cell lines analyzed. We had previously shown 1p22 to be a frequent site of allelic loss in MM (Lee et al., 1996), which implicated the involvement of a tumor suppressor gene (TSG) at this location. The aim of this letter is to report the results of our studies of BCL10 as a candidate for the 1p22 putative TSG in MM, and to prompt further discussion about the potential role of this gene in human malignancy.
Fifty MM cell lines were examined for loss of heterozygosity (LOH). Since YAC 929E1 contains BCL10 (Willis et al., 1999), two microsatellite markers, D1S2766 and D1S1618, were selected for analysis, as they were determined through a database search (http://www-genome. wi.mit.edu) and PCR analysis to map to this YAC. Overall, 25 of 45 informative cases (55.6%) showed LOH of at least one of these two loci, with the higher frequency of allelic loss being at marker D1S1618 (18 out of 30 
